950 related articles for article (PubMed ID: 15356308)
1. Thiazolidinediones.
Yki-Järvinen H
N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
[No Abstract] [Full Text] [Related]
2. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
3. Polycystic ovary syndrome and insulin resistance.
Plosker SM
Med Health R I; 2003 Jan; 86(1):12-5. PubMed ID: 12633015
[No Abstract] [Full Text] [Related]
4. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
5. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Lotz N
MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
[No Abstract] [Full Text] [Related]
6. Pleiotropic effects of thiazolidinediones.
Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
[TBL] [Abstract][Full Text] [Related]
7. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome.
Practice Committee of the American Society for Reproductive Medicine
Fertil Steril; 2006 Nov; 86(5 Suppl 1):S221-3. PubMed ID: 17055827
[No Abstract] [Full Text] [Related]
8. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
Szymborska-Kajanek A; Strojek K
Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
[No Abstract] [Full Text] [Related]
9. [New antidiabetic in "virtual reality". Eye to eye with insulin resistance].
MMW Fortschr Med; 2000 May; 142(19):52. PubMed ID: 10850084
[No Abstract] [Full Text] [Related]
10. [Against insulin resistance. Insulin sensitizers].
Verspohl EJ; Weiland F
Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
[No Abstract] [Full Text] [Related]
11. [Mechanisms of action of thiazolidinediones].
Girard J
Diabetes Metab; 2001 Apr; 27(2 Pt 2):271-8. PubMed ID: 11452221
[TBL] [Abstract][Full Text] [Related]
12. Polycystic ovary syndrome.
Ehrmann DA
N Engl J Med; 2005 Mar; 352(12):1223-36. PubMed ID: 15788499
[No Abstract] [Full Text] [Related]
13. [Rosiglitazone (BRL-49653)].
Oka Y
Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030
[No Abstract] [Full Text] [Related]
14. Use of metformin in pediatric age.
Brufani C; Fintini D; Nobili V; Patera PI; Cappa M; Brufani M
Pediatr Diabetes; 2011 Sep; 12(6):580-8. PubMed ID: 21366813
[No Abstract] [Full Text] [Related]
15. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
16. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Lehmann DF; Lohray BB
J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500
[No Abstract] [Full Text] [Related]
17. Cardiovascular risk in women with polycystic ovary syndrome.
Cho LW; Atkin SL
Minerva Endocrinol; 2007 Dec; 32(4):263-73. PubMed ID: 18091663
[TBL] [Abstract][Full Text] [Related]
18. [Glitazones more than hypoglycemics in type 2 diabetes].
Sjöholm A
Lakartidningen; 2007 Oct 24-30; 104(43):3201-3. PubMed ID: 18018938
[No Abstract] [Full Text] [Related]
19. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Omer Z; Cetinkalp S; Akyildiz M; Yilmaz F; Batur Y; Yilmaz C; Akarca U
Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):18-23. PubMed ID: 19667999
[TBL] [Abstract][Full Text] [Related]
20. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
[Next] [New Search]
